Emmanuelle Sabbah-Petrover

Title: Emmanuelle Sabbah-Petrover: Innovator in Cancer Immunotherapy

Introduction

Emmanuelle Sabbah-Petrover is a prominent inventor based in Paris, France. She has made significant contributions to the field of immunotherapy, particularly in the development of antibodies targeting cancer cells. Her innovative work has the potential to transform cancer treatment and improve patient outcomes.

Latest Patents

Emmanuelle holds a patent for "Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof." This invention focuses on monoclonal, chimeric, or humanized antibodies that recognize a specific epitope common to human acidic and basic isoferritins. The anti-ferritin antibodies can be utilized in pharmaceutical compositions for immunotherapy or radioimmunotherapy, targeting various cancer cells in mammals. The patent also discloses methods for delivering these antibodies to cancerous lymph cells, pancreatic cells, lymphatic endothelium cells, and liver cells, as well as treatment methods for pancreatic cancer, hepatocellular carcinomas, Kaposi's sarcoma, and Hodgkin's lymphoma.

Career Highlights

Emmanuelle is associated with Immune Pharmaceuticals Ltd., where she continues to advance her research and development efforts. Her work is characterized by a commitment to innovation and a focus on addressing critical challenges in cancer treatment.

Collaborations

Emmanuelle collaborates with notable colleagues, including Jean Kadouche and Olivier Chose. These partnerships enhance her research capabilities and contribute to the advancement of her projects.

Conclusion

Emmanuelle Sabbah-Petrover is a trailblazer in the field of cancer immunotherapy, with a patent that showcases her innovative approach to targeting cancer cells. Her contributions are poised to make a significant impact on the future of cancer treatment.